News & Updates

November 5, 2018

• The Sage Group, an internationally recognized consulting group, has been appointed to identify a commercial partner with a special focus on the US market

• ASIT biotech has developed an innovative immunotherapy product entering a confirmatory phase III study in grass pollen induced allergic rhinitis, requiring only a 3-week treatment course prior to the...

September 7, 2018

Stockholm, Sweden, 8 September 2018 – Moberg has appointed The Sage Group to lead the BUPIZENGE™ partnering program.

Moberg Pharma is a rapidly growing, publicly-traded, Swedish pharmaceutical company that commercializes proprietary and acquired products in the global market. Initially, the company specialized in innovative topical treatments in niche indi...

August 3, 2018

Sage Group is working with Solvotrin Therapeutics (“Solvotrin”), based in Cork, Ireland. Solvotrin is a drug development company focused on optimising established therapies, vitamins and minerals using innovative science to deliver value for significant unmet clinical needs.

Solvotrin are seeking both licensing and collaboration partners for Solvotrin, to...

August 2, 2018

Copenhagen, Denmark, 2 August 2018 – Anapa Biotech (“Anapa”; www.meltplex.com) is a Copenhagen - based company with novel intellectual property and a first-in-class approach to ultrahigh performance multiplexing for molecular diagnostic assays.

Following a strategic review and four years of technical development and IP filing, Anapa is pleased to announce...

January 16, 2018

Kitov Pharmaceuticals, based in Israel, announces their lead product KIT-302. It combines Celecoxib (a COX-2 selective NSAID, the active ingredient in Pfizer’s Celebrex®) and Amlodipine (a neuronal calcium channel blocker), both successful products on the market.

KIT-302 (Pending FDA approval will be named Concensi for the US market) demonstrated 2.5x bett...

December 26, 2017

SAJE Pharma (www.sajepharma.com) seeks an acquirer or licensee of its GSNORi (S-nitrosoglutathione reductase inhibitor) drug discovery platform. This is a novel approach based on regulating the nitrosylation signal transduction pathways which will lead to multiple drug candidates to treat many major-market diseases driven by inflammation, oxidant damage,...

November 21, 2017

Zora Biosciences (“Zora”; www.zora.fi) is a privately funded, Finnish-based diagnostics company with novel intellectual property and a breakthrough approach to assessing predilection to disease in two distinct areas: (1) Cardiovascular and Diabetes Risk with their CERT test and (2) Ovarian Cancer with their OCDT test.

Zora is seeking a global strategic par...

September 22, 2017

Metabolomic Diagnostics (“MetaDx”; www.metabolomicdiagnostics.com) is a Cork, Ireland-based predictive biomarker diagnostics company with novel intellectual property and a breakthrough approach to predicting pre-eclampsia in pregnant women. It also has a pipeline of additional metabolomic biomarker tests for additional health issues faced by pregnant wome...

Please reload